首页> 外文期刊>Journal of Surgical Oncology >The concentration of the cleaved suPAR forms in pre- and postoperative plasma samples improves the prediction of survival in colorectal cancer: A nationwide multicenter validation and discovery study
【24h】

The concentration of the cleaved suPAR forms in pre- and postoperative plasma samples improves the prediction of survival in colorectal cancer: A nationwide multicenter validation and discovery study

机译:在术后和术后血浆样品中切割的SUPAR形式的浓度改善了结直肠癌中存活的预测:全国范围内的多中心验证和发现研究

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Background and Objectives The aim was to evaluate the prognostic biomarker potential of the soluble urokinase-type plasminogen activator receptor (suPAR) in plasma samples collected pre- and postoperatively from patients resected for colorectal cancer (CRC). Methods Patients with CRC were recruited prospectively at six centers from 2006 to 2008. Preoperative plasma samples were available from 494 patients and from 328 of these patients at 6 months postoperatively. Determinations of intact soluble uPAR (suPAR) suPAR(I-III) and the cleaved forms suPAR(I-III) + (II-III) and uPAR(I) were performed. Clinical data were retrieved retrospectively. Results In a multivariable model based on preoperative plasma samples suPAR(I-III) + (II-III) and uPAR(I) showed an independent statistically significant association to long term survival. When including the change in biomarker level between the pre- and postoperatively samples the hazard ratios were 3.06 (95% confidence interval [CI], 1.78-5.28; P < .0001) and 2.24 (95% CI, 1.59-3.16; P < .0001) for suPAR(I-III) + (II-III) and uPAR(I), respectively. A one-unit decrease in biomarker levels between the pre- and postoperative levels resulted in a 55% and 34% reduction in the risk estimate of death for suPAR(I-III) + (II-III) and uPAR(I), respectively. Conclusion This study validates previously findings regarding the prognostic significance of suPAR in preoperative samples. The inclusion of postoperative samples added further prognostic information.
机译:背景和目的目的是评估预先和术后切除结直肠癌(CRC)的血浆样品中可溶性尿激酶型纤溶酶原激活剂受体受体(SUPAR)的预后生物标志物电位。方法从2006年至2008年六个中心招募了CRC患者。术前等血浆样品可从494名患者和328名患者术后获得。进行完整可溶性Upar(SUPAR)SUPAR(I-III)和切割形式SUPAR(I-III)+(III III)和UPAR(I)的测定。回顾性地检索临床数据。结果基于术前等离子体样品的多变量模型(I-III)+(III)+(IIII)和UPAR(I)表现出与长期存活的独立统计学意义。当包括预和术后样品之间的生物标志物水平的变化时,危险比为3.06(95%置信区间[CI],1.78-5.28; P <.0001)和2.24(95%CI,1.59-3.16; P < .0001)对于Supar(I-III)+(II-III)和UPAR(I)。预期和术后水平之间的生物标志物水平的单调降低导致Supar(I-III)+(III)和UPAR(I)的死亡风险估计减少了55%和34% 。结论本研究先前验证了术前样品中超级预后显着性的结果。包含术后样品的进一步预后信息。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号